fda warning letters compounded tirzepatide 2024 2025 US Letters: Considerations for LDTs including Timelines FDA warns Ozempic and Mounjaro

Women and hormonal considerations Both medications affect hormonal balance through weight loss

GLP-1 receptor agonists are licensed for type 2 diabetes and weight management, not specifically for cholesterol reduction

Lyophilized: Hold at 20 C (4 F) or colder for long-term keeping

multiple sessions typically required Subcision procedures surgical release of fibrous septa shows promise but carries procedural risks including bruising, pain, and scarring Vacuum-assisted massage devices limited evidence for sustained benefit beyond treatment period The National Institute for Health and Care Excellence (NICE) does not provide specific guidance on cellulite treatment as it is considered a cosmetic rather than medical concern

For a complete list of potential side effects, visit the drug manufacturer websites for: Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide), the three GLP-1 medications that are FDA-approved for overweight and obesity

These changes occur within 1224 weeks at therapeutic doses and are independent of statin use